Home
>
>
Press
>
Solvay’s cell-based production facility for Influenza vaccines validated and operational
Welcome
Research and development
Clinical Trials Database
Clinical Trial Results Disclosure
Clinical Trials Results - Marinol
Clinical Trials Results - Androgel
Clinical Trial Results - Tricor
Four therapeutic areas
R&D Process
R&D Pipeline
Scientific collaborations
Products
Cardiometabolics
Omacor®
Teveten®
Tricor/Lipanthyl®
Gastroenterology
Dicetel®
Duphalac®
Duspatal®
Influenza vaccines
Influvac®
Neuroscience
Duodopa®
Luvox®
Serc®
Pancreatic enzymes
Creon®
Women's and men's health
AndroGel®
Duphaston®
Femoston®
Contacts
News
version:
[FR]
-
[NL]
-
> September 09, 2009<
Solvay’s cell-based production facility for Influenza vaccines validated and operational
|
Email this
|
© Abbott • Important information :
Privacy Policy
-
Disclaimer
-
Welcome
• If you have any comments, please contact the
webmaster
Date of last update: 23/7/2010
